Accueil   Diary - News   All news APCure - « Orphan Drug Designation » for LTVax

APCure – « Orphan Drug Designation » for LTVax

APCure receives the « Orphan Drug Designation » for LTVax in Merkel cell carcinoma and validates its preclinical results

 

 

APCure, a pre-clinical stage biotechnology company, is pleased to announce that the European Medicines Agency (EMA) has granted the « Orphan Drug Designation » to LTVax for the treatment of Merkel Cell Carcinoma.

LTVax is a « first-in-class » immunotherapy inducing an immune response against the Large-T antigen of Merkel Cell Polyomavirus (MCPyV), an oncovirus responsible for the development of 80 % of Merkel cell carcinomas. Developed by APCure, LTVax is based on the proprietary BacVac technology created by the TheREx lab at the Grenoble Alpes University. This technology uses a live, attenuated, bacterial vector to teach the patient immune system to recognize and destroy cancer cells. The development of other products based on this technology is currently in progress.


Read the press release

 

 

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree